CompletedNCT07359209
Berberine Improving Cognitive Impairments in Schizophrenia
Medication studyAges 18–65China
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- TianjinSee all locations and recruitment
Study information
Study start dateStarted: July 21, 2023
- Recruitment status
- Completed
- Enrollment listed in the registry
- 124
- Sponsor
- Tianjin Anding Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Not clearly listed
- Locations
- China
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT07359209
- Official title
Show the full official title
Study on the Mechanism s of Berberine Improving Cognitive Impairments in Schizophrenia Based on Gut-brain Axis
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Tianjin
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Tianjin Anding Hospital, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Berberine.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
